Chimerix ((CMRX)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Chimerix is conducting a Phase 3 clinical study titled ‘ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.’ The study aims to evaluate if ONC201 can improve overall and progression-free survival in patients with this specific type of brain tumor after they have completed radiotherapy. This research is significant as it targets a challenging and aggressive cancer subtype.
The intervention being tested is a drug called Dordaviprone (ONC201), administered in two experimental groups with different dosing schedules, and compared against a placebo group. The drug is intended to extend survival rates in patients with H3 K27M-mutant diffuse glioma.
The study is designed as a randomized, double-blind, placebo-controlled trial with a parallel intervention model. It involves triple masking, meaning that participants, care providers, and investigators are unaware of the group assignments. The primary purpose of the study is treatment-focused.
The study began on January 23, 2023, and is currently recruiting participants. The last update was submitted on July 7, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
This clinical update could influence Chimerix’s stock performance positively if the results show significant benefits, as it would enhance the company’s portfolio in oncology treatments. Investors should watch for developments, especially in comparison to competitors in the glioma treatment space.
The study is ongoing, and further details are available on the ClinicalTrials portal.